Novel HIF2A mutations disrupt oxygen sensing, leading to polycythemia, paragangliomas, and somatostatinomas Blood, Mar 2013; 121: 2563 - 2566.
[anti-HA]
Regulation of the PI3-K/Akt Survival Pathway in the Rat Endometrium Biol Reprod, Mar 2013; 88: 79.
[Akt3]
RNA elements directing in vivo assembly of the 7SK/MePCE/Larp7 transcriptional regulatory snRNP Nucleic Acids Res., Mar 2013; 10.1093/nar/gkt159.
[LA]
Ruxolitinib as potential targeted therapy for patients with JAK2 rearrangements Haematologica, Mar 2013; 98: 404 - 408.
[JAK2]
Homo sapiens mitogen-activated protein kinase 10 (MAPK10), transcript variant 1
Synonyms:
JNK3; JNK3A; p493F12; p54bSAPK; PRKM10; SAPK1b
Immunogen
A synthetic phospho-peptide corresponding to residues surrounding threonine 221 of human JNK3 was used as immunogen. The antibody will detect JNK1 (pT183), JNK2(pT183) and JNK3 (pT221).
Buffer
Store at -20 °C. Buffer: Antibody buffer, sodium azide, glycerol, and BSA. Stable for 12 months from date of receipt.
C-Jun N-terminal kinases (JNK) are distantly related to mitogen-activated protein kinases (ERKs) and are activated by dual phosphorylation on Tyr and Thr. The JNK protein kinase group consists of three isoforms (JNK1, 2, and 3) and regulates transcription activity of the AP-1 complex, and release and regulation of cytochome c (1). JNK becomes activated in vivo in response to pro-inflammatory cytokines or cellular stresses. Its full activation requires the phosphorylation of a threonine and a tyrosine residue in a Thr-Pro-Tyr motif, which can be catalysed by the protein kinases mitogen-activated protein kinase kinase MKK4 and MKK7 (2). Unlike other JNK isoforms, JNK3 is only expressed in the heart and nervous system. JNK3 has been implicated in stress-induced neuronal apoptosis (3).
Related Pathway
Apoptosis
Focal Adhesion
MAPK signaling pathway
Toll-like receptor signaling pathway
Wnt Signaling Pathway
* Shipping is in business days
* OriGene provides validated application data and protocol, with money back guarantee.
Western blot analysis on NIH/3T3 cell lysates using anti-Phospho-JNK1 (pT183) / JNK2 (pT183) / JNK3 (pT221) RabMAb. Cells were either (A) untreated (B) treated with Anisomycin.
